A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Autor: Yinghui Zhang, Marcel Smid, Jichao He, Ronan P. McLaughlin, Vera E. van der Noord, John W.M. Martens, Jevin Redel, Bob van de Water, John A. Foekens

Publikováno v: Breast Cancer Research : BCR
Breast Cancer Research, 21, 77
Breast Cancer Research
Breast Cancer Research, Vol 21, Iss 1, Pp 1-15 (2019)
Breast Cancer Research, 21:77. BioMed Central Ltd.

Background The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge. Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling pathways in TNBC, resistan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13cadad1eae435379a4058f43e2b53bf
https://pubmed.ncbi.nlm.nih.gov/31262335

Additional file 4: of A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Autor: McLaughlin, Ronan, Jichao He, Noord, Vera, Jevin Redel, Foekens, John, Martens, John, Smid, Marcel, Yinghui Zhang, Water, Bob

Figure S2. EGFR-negative TNBC cell line SUM185PE is insensitive to co-treatment with lapatinib and PHA-767491. a. Immunofluorescence imaging of EGFR-positive (SKBR7) and EGFR-negative (SUM185PE) TNBC cell lines. Cells were fixed using 1% paraformalde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2bace8a90501037f66f327a026a72dbe

Additional file 6: of A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Autor: McLaughlin, Ronan, Jichao He, Noord, Vera, Jevin Redel, Foekens, John, Martens, John, Smid, Marcel, Yinghui Zhang, Water, Bob

Figure S4. siRNA-mediated silencing of cdc7 and/or CDK9 in combination with lapatinib. a. Silencing cdc7 or CDK9 synergises with lapatinib to inhibit proliferation in SKBR7 cells but not Hs578T or BT549 cells. % proliferation 4 days post-treatment wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ff9f4f14bd75a4803b33da4a7421013

Additional file 5: of A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy

Autor: McLaughlin, Ronan, Jichao He, Noord, Vera, Jevin Redel, Foekens, John, Martens, John, Smid, Marcel, Yinghui Zhang, Water, Bob

Figure S3. EGFR-TKIs and PHA-767491 synergise to induce G2/M cell cycle arrest and apoptosis. a. Cell cycle distribution histograms of Hs578T and SKBR7 cells after 48-h treatment with EGFR-TKIs (lapatinib, erlotinib or gefitinib at 3.16 μM) alone or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e2f61d1ae0e12466bfbf87b10d2382b